SYMBIOTEC Share Price Target 2040
CAGR-based price projection for Symbiotec Pharmalab Limited (SYMBIOTEC) targeting 2040, derived from official NSE exchange closing prices.
Current Market Snapshot
Year-by-Year Price Projection
| Year | Bear Case | Base Case | Bull Case |
|---|---|---|---|
| 2027 | Rs 1,242 | Rs 1,307 | Rs 1,496 |
| 2028 | Rs 1,287 | Rs 1,427 | Rs 1,867 |
| 2029 | Rs 1,334 | Rs 1,557 | Rs 2,331 |
| 2030 | Rs 1,383 | Rs 1,700 | Rs 2,910 |
| 2031 | Rs 1,434 | Rs 1,855 | Rs 3,633 |
| 2032 | Rs 1,486 | Rs 2,024 | Rs 4,536 |
| 2033 | Rs 1,540 | Rs 2,209 | Rs 5,662 |
| 2034 | Rs 1,597 | Rs 2,411 | Rs 7,069 |
| 2035 | Rs 1,655 | Rs 2,632 | Rs 8,825 |
| 2036 | Rs 1,715 | Rs 2,872 | Rs 11,017 |
| 2037 | Rs 1,778 | Rs 3,134 | Rs 13,754 |
| 2038 | Rs 1,843 | Rs 3,421 | Rs 17,171 |
| 2039 | Rs 1,910 | Rs 3,733 | Rs 21,437 |
| 2040 | Rs 1,980 | Rs 4,075 | Rs 26,762 |
Frequently Asked Questions
What is the SYMBIOTEC share price target for 2040?
Based on historical growth analysis, the SYMBIOTEC share price target for 2040 ranges from Rs 1,980 (conservative) to Rs 4,075 (base case) to Rs 26,762 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.
What is the current share price of SYMBIOTEC?
The current market price of SYMBIOTEC (Symbiotec Pharmalab Limited) is Rs 1,198.00. The 52-week high is Rs 1,198.00 and 52-week low is Rs 1,003.35.
Is SYMBIOTEC a good stock to buy for the long term?
Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.
What methodology does BrokerLens use for SYMBIOTEC price targets?
BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 3.7% CAGR), Base (9.1% CAGR), and Bull (optimistic at 24.8% CAGR). These are statistical projections, not guaranteed forecasts.